Designing L-type Amino Acid Transporter 1-targeting Cancer Theranostic Radiopharmaceuticals: A Molecular Docking Simulation
Chempublish Journal · 20.01.2026 · 9 (2) · 329-346
DOI: 10.22437/chp.v9i2.48053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chempublish Journal, online erschienen am 20.01.2026. Verfasst von Holis Abdul Holik und 6 weiteren Autor:innen.
Abstract (Originalsprache)
L-type amino acid transporter 1 (LAT1) is a potential pan-cancer theranostic molecular target. The LAT1 inhibitory potencies of eight theranostic radiopharmaceuticals designed based on a potent LAT1 inhibitor ADPB (in vitro pIC50 6.19), were estimated in molecular docking simulations. The designs comprised ADPB as a carrier molecule with/without 6-aminohexanoic acid (Ahx) linker, a chelating agent, and a radiometal (68Ga or 177Lu). JPH203, the most potent LAT1 inhibitor (pIC50 7.22), was utilized as a benchmark compound. A set of known LAT1 ligands (n = 15) were first docked into LAT1 to build the docking protocol. Adding a linker improved the LAT1 inhibitory potency of DOTA-conjugated and NODAGA-conjugated ADPB-based theranostic radiopharmaceutical designs. 177Lu-DOTA-Ahx-ADPB has the exceptional LAT1 inhibitory potency (pIC50 51.55 ± 17.06) while 177Lu-DOTA-ADPB, its non-linker counterpart, has LAT1 inhibitory potency significantly higher than the native JPH203. Both 177Lu-DOTA-Ahx-ADPB and 177Lu-DOTA-ADPB have strong bonds with key amino acids on the LAT1 binding pocket, particularly Asn258, Tyr259, and the gating residue Phe252. Our findings provide a quantitative and illustrative understanding of the LAT1 inhibitory potency of LAT1-targeting theranostic radiopharmaceutical designs relevant to the rational design of pan-cancer radiotheranostic drugs. Keywords: LAT1, pan-cancer, theranostic radiopharmaceutical, MOE, chelating agent, gallium-68, lutetium-177.
Zitieren
APA
Holik, H. A., Achmad, A., Ibrahim, F. M., Elaine, A. A., Stefanus, J., Sudarmanto, B. A. S., & Kartamihardja, A. H. S. (2026). Designing L-type Amino Acid Transporter 1-targeting Cancer Theranostic Radiopharmaceuticals: A Molecular Docking Simulation. Chempublish Journal, 9(2), 329-346. https://doi.org/10.22437/chp.v9i2.48053
Vancouver
Holik HA, Achmad A, Ibrahim FM, Elaine AA, Stefanus J, Sudarmanto BAS, et al. Designing L-type Amino Acid Transporter 1-targeting Cancer Theranostic Radiopharmaceuticals: A Molecular Docking Simulation. Chempublish Journal. 2026;9(2):329-346. doi:10.22437/chp.v9i2.48053
BibTeX
@article{Holik2026,
author = {Holik, Holis Abdul and Achmad, Arifudin and Ibrahim, Faisal Maulana and Elaine, Angela Alysia and Stefanus, Jonathan and Sudarmanto, B.S. Ari Sudarmanto and Kartamihardja, Achmad Hussein S.},
title = {Designing L-type Amino Acid Transporter 1-targeting Cancer Theranostic Radiopharmaceuticals: A Molecular Docking Simulation},
journal = {Chempublish Journal},
year = {2026},
volume = {9},
number = {2},
pages = {329--346},
doi = {10.22437/chp.v9i2.48053}
}
EUVIMED